Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Clinical Trials
523
Trial Phases
6 Phases
Drug Approvals
9
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (419 trials with phase data)• Click on a phase to view related trials
A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2025-09-02
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 22
- Registration Number
- NCT07149415
A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old
- Conditions
- Healthy Volunteer
- Interventions
- Drug: BIIB142Drug: BIIB142-Matching Placebo
- First Posted Date
- 2025-08-21
- Last Posted Date
- 2025-09-11
- Lead Sponsor
- Biogen
- Target Recruit Count
- 78
- Registration Number
- NCT07133828
- Locations
- 🇺🇸
PPD Development, LP, Las Vegas, Nevada, United States
A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Biogen
- Target Recruit Count
- 200
- Registration Number
- NCT07047820
- Locations
- 🇺🇸
CVS Health, Woonsocket, Rhode Island, United States
A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy Adults Aged 18 to 55
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Biogen
- Target Recruit Count
- 52
- Registration Number
- NCT07019064
- Locations
- 🇺🇸
Trialmed formerly PPD, Austin Clinic, Austin, Texas, United States
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
- Conditions
- Primary Membranous Nephropathy
- Interventions
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 180
- Registration Number
- NCT06962800
- Locations
- 🇺🇸
James J Peters Veterans Administration Medical Center - NAVREF - PPDS, Bronx, New York, United States
🇺🇸Academic Medical Research Institute, Los Angeles, California, United States
🇺🇸Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDS, Pontiac, Michigan, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 101
- Next
News
Drug Hunter Secures Seed Investment to Expand Knowledge Platform for Pharmaceutical R&D
Drug Hunter, a knowledge platform serving over 200 pharmaceutical R&D organizations including Eli Lilly, Biogen, and NIH, announced seed funding led by Teamworthy Ventures to accelerate drug discovery insights.
FDA Moves to Eliminate Expert Advisory Panels for Individual Drug Reviews Under Trump Administration
The FDA under President Trump is abandoning its decades-old policy of convening outside expert panels to review individual drug applications, with officials claiming these meetings are redundant and time-consuming.
FDA Accepts IND Application for BIIB142, First IRAK4 Degrader to Enter Clinical Development for Autoimmune Diseases
The FDA has accepted Biogen's IND application for BIIB142, an IRAK4 protein degrader developed through collaboration with C4 Therapeutics, marking the first IRAK4 degrader to advance toward clinical trials for autoimmune diseases.
FDA Approves Weekly Autoinjector for Eisai's Alzheimer's Drug Leqembi, Enabling At-Home Treatment
The FDA has approved a once-weekly autoinjector version of Eisai's Alzheimer's drug Leqembi, branded as Leqembi IQLIK, marking the first at-home dosing option for amyloid-based Alzheimer's therapy.
FDA Recommends Enhanced Brain Monitoring for Alzheimer's Patients on Leqembi Following Six Early Deaths
The FDA is requiring additional brain scans between the second and third Leqembi infusions after identifying six deaths early in treatment related to brain swelling complications.
Biogen Advances Litifilimab Development with Phase 3 Extension Study and Novel Drug Delivery Research for Lupus Treatment
Biogen is conducting a Phase 3 long-term extension study evaluating litifilimab's continuous safety and efficacy in adults with active systemic lupus erythematosus, with completion expected in August 2025.
Eli Lilly Neuroscience Chief Anne White to Retire After Leading Alzheimer's Drug Launch
Eli Lilly announced that Anne White, head of its neuroscience division, will retire in December after a 30-year career at the company.
Ionis Pharmaceuticals Reports Strong Q2 2025 Results, Raises Guidance on TRYNGOLZA Success
Ionis Pharmaceuticals delivered $19 million in net product sales for TRYNGOLZA in Q2 2025, driving a doubling of total revenue to $452 million compared to the same period last year.
Roche Launches Clinical Trial for Trontinemab to Prevent Alzheimer's Disease
Roche announced plans to test Trontinemab, an experimental drug designed to delay or prevent Alzheimer's disease symptoms in at-risk individuals.
Biogen's Zurzuvae Receives EMA Panel Recommendation for Postpartum Depression Treatment
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended marketing authorization for Biogen's ZURZUVAE (zuranolone) for treating postpartum depression in adults following childbirth.